CDKN2A and neoplasm: Taken together, these observations indicate that Ad-ERE73 (1 + 2)-ARF (−13)-TK and Ad-ERE73 (3 + 4)-ARF (−13)-TK could effectively reduce tumor cell growth without obvious systemic side effects.